TECHNOLOGY SUMMARY

Zylö Therapeutics licensed an innovative topical drug delivery system in 2017. The system, based on silica-derived microparticles called Z-pods®, held the promise of enhancing the bioavailability of many topically applied active ingredients (AIs) for animals, plants, and humans. Zylö has advanced the technology and readied it for commercialization.

AREA/MATURITY/AWARDS

Primary Application Area: Biotech, Pharma, Health

Technology Development Status: Ready to Market

Technology Readiness Level: TRL 7

Vetted Programs/Awards: Per Technology Summary above, Zylö has been awarded multiple Phase I and Phase II SBIR grants by NIH to further develop and commercialize the Z-pod® technology. Zylö is also a partner on a Department of Defense grant related to wound healing per above.

SHOWCASE SUMMARY

Organization Type: Small to Medium Enterprise

Website: http://www.zylotherapeutics.com

MARKET KEYWORDS

Market Keywords: topical application, bioavailability, erectile dysfunction, lupus, nail fungus, wound healing